Haag-Molkenteller C

No ORCID on file · 1 paper in corpus

2022

Efficacy and safety of vibegron for the treatment of irritable bowel syndrome in women: Results of a randomized, double-blind, placebo-controlled phase 2 trial.

Neurogastroenterology and motility ·doi:10.1111/nmo.14448

BackgroundPreclinical and clinical studies suggest that β3 -adrenergic receptor activation may be a novel target for treating abdominal pain and gastrointestinal motility dysfunction in patients with irritable bowel syndrome (IBS). This pro…